NanoViricidesNNVC
NNVC
About: Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Employees: 7
0
Funds holding %
of 7,324 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
5,100% more call options, than puts
Call options by funds: $104K | Put options by funds: $2K
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
6% more funds holding
Funds holding: 36 [Q4 2024] → 38 (+2) [Q1 2025]
0.64% less ownership
Funds ownership: 10.16% [Q4 2024] → 9.52% (-0.64%) [Q1 2025]
17% less capital invested
Capital invested by funds: $2.09M [Q4 2024] → $1.74M (-$346K) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for NNVC.
Financial journalist opinion
Based on 11 articles about NNVC published over the past 30 days
Positive
Proactive Investors
1 day ago
NanoViricides says antiviral candidate NV-387 could address global measles surge
NanoViricides (NYSE-A:NNVC) said on Wednesday that its antiviral candidate NV-387 could play a key role in addressing the growing number of measles cases globally, particularly in industrialized nations including the US, Canada, the UK, and the EU. The company said NV-387 has shown safety and effectiveness in preclinical studies using humanized mouse models and has completed a Phase I clinical trial with no reported adverse events, supporting its potential as a measles treatment.
Neutral
Accesswire
1 day ago
Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides
SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced that its drug candidate NV-387 is the weapon necessary for combatting growing cases of measles worldwide, especially in the industrialized world including, USA, Canada, UK, and European Union.
Positive
Proactive Investors
1 week ago
NanoViricides eyes revenue opportunities with broad-spectrum antiviral NV-387
NanoViricides (NYSE-A:NNVC) said on Wednesday that its broad-spectrum antiviral candidate NV-387 has shown strong preclinical efficacy against multiple viruses, positioning it as a potential tool in global pandemic preparedness. The Connecticut-based biotech firm said its NV-387 compound has demonstrated effectiveness in animal studies against a wide range of viral threats, including MPox, Smallpox, Measles, Influenza, Coronaviruses, and other orthopoxviruses.
Neutral
Accesswire
1 week ago
NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value
SHELTON, CONNECTICUT / ACCESS Newswire / July 23, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, explains that the strong effectiveness of its broad-spectrum antiviral drug against all viruses that the drug NV-387 was tested against to date will drive significant valuation for its portfolio.
Positive
Proactive Investors
1 week ago
NanoViricides says lead antiviral boosted survival in measles-infected mice
NanoViricides (NYSE-A:NNVC) said on Monday that its broad-spectrum antiviral candidate, NV-387, showed strong effectiveness in preclinical studies using a humanized animal model. The Connecticut-based biotech firm reported increased survival in mice infected with a lethal dose of the measles virus by 130%, extending average survival time to 17 days compared to 7.4 days in untreated animals.
Neutral
Accesswire
1 week ago
Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides
SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced that it has achieved significant success in developing a drug against Measles.
Positive
Proactive Investors
2 weeks ago
NanoViricides says MPox drug candidate NV-387 poised for Phase II trial as WHO extends global health emergency
NanoViricides (NYSE-A:NNVC) is preparing for Phase II clinical testing in Africa, following the World Health Organization's recent extension of the Public Health Emergency of International Concern (PHEIC) for the Mpox virus outbreak. The extension, announced on July 10, comes amid rising cases of the Clade I strain of the Mpox virus (MPXV) in Africa, and sporadic travel-related cases outside the region, including the US, that pose a risk of sustained transmission.
Neutral
Accesswire
2 weeks ago
WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides
SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, comments on the extension of the MPox Public Health Emergency of International Concern (PHEIC) by WHO. The Director General of WHO has extended the PHEIC declaration for MPox epidemic according to a WHO news release dated July 10, 2025, following continuing upsurge of the MPox virus (MPXV) epidemics in the African region[1].
Positive
Proactive Investors
2 weeks ago
NanoViricides positioned at forefront of Mpox treatment efforts, says Zacks
NanoViricides (NYSE-A:NNVC) is preparing to launch a Phase 2 clinical trial of its lead antiviral candidate NV-387 for the treatment of Mpox Clade I in the Democratic Republic of Congo (DRC), following ethics approval from the country's health ministry in May, according to a research note by Zacks Small Cap Research. The trial will test the efficacy and safety of NV-387, a broad-spectrum antiviral developed using NanoViricides' proprietary nanomedicine platform, in up to 80 hospitalized patients.
Positive
Proactive Investors
2 weeks ago
NanoViricides nears completion of clinical trial design for MPox treatment
NanoViricides (NYSE-A:NNVC) said on Monday it is close to finalizing the design of a Phase II adaptive clinical trial for its lead candidate NV-387 to treat MPox virus Clade 1a and 1b infections. The trial aims to assess safety, tolerability, and antiviral effectiveness in approximately 80 patients, with the initial Phase IIa portion to be conducted at a single site in the Democratic Republic of Congo (DRC).
Charts implemented using Lightweight Charts™